
Spero Therapeutics SPRO
$ 0.74
-9.76%
Spero Therapeutics ROA Ratio | SPRO
Annual ROA Ratio Spero Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.44 | -62.03 | 12.5 | -37.19 | -52.49 | -51.01 | -57.42 | -32.29 | -41.45 | - | -141.5 | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.5 | -141.5 | -45.04 |
Quarterly ROA Ratio Spero Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -24.82 | 1.8 | 17.17 | 11.53 | -53.1 | -52.16 | -61.34 | -51.05 | -4.09 | 5.6 | 5.47 | 1.24 | 69.0 | 53.89 | 20.86 | 10.14 | -102.79 | -100.25 | -70.7 | -61.73 | -56.75 | -53.24 | -55.65 | -57.29 | -68.73 | -72.42 | -65.22 | -54.1 | -38.77 | -30.71 | -33.69 | -42.75 | -50.33 | -80.92 | -108.61 | -136.88 | -173.43 | -181.02 | -41.4 | -52.36 | -45.86 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 69.0 | -181.02 | -45.99 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - | ||
|
Lyra Therapeutics
LYRA
|
-80.09 | - | - | $ 24.9 M | ||
|
Brickell Biotech
BBI
|
-49.15 | - | -5.38 % | $ 6.06 M | ||
|
Applied Therapeutics
APLT
|
-121.84 | - | - | $ 8.42 M | ||
|
ESSA Pharma
EPIX
|
-22.28 | - | - | $ 8.86 M | ||
|
Generation Bio Co.
GBIO
|
-56.95 | - | - | $ 344 M | ||
|
Clearside Biomedical
CLSD
|
-136.72 | - | - | $ 25.3 M | ||
|
Merus N.V.
MRUS
|
-27.51 | - | - | $ 5.78 B | ||
|
RAPT Therapeutics
RAPT
|
-54.04 | - | - | $ 2.36 B | ||
|
Annexon
ANNX
|
-74.47 | $ 3.11 | -8.94 % | $ 482 M | ||
|
Acasti Pharma
ACST
|
-11.69 | - | 4.01 % | $ 150 M | ||
|
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | ||
|
Galapagos NV
GLPG
|
9.42 | - | - | $ 1.83 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
-5.16 | - | -4.36 % | $ 27 M | ||
|
Avenue Therapeutics
ATXI
|
-99.25 | - | -52.27 % | $ 4.45 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
-55.34 | $ 4.63 | 21.05 % | $ 20 M | ||
|
Achieve Life Sciences
ACHV
|
-130.77 | $ 6.78 | 0.89 % | $ 296 M | ||
|
Leap Therapeutics
LPTX
|
3.06 | - | 368.57 % | $ 41.9 M | ||
|
Lumos Pharma
LUMO
|
-83.75 | - | - | $ 35.3 M | ||
|
Gamida Cell Ltd.
GMDA
|
-46.76 | - | -18.25 % | $ 5.04 M | ||
|
Axcella Health
AXLA
|
-428.94 | - | -16.42 % | $ 249 M | ||
|
Metacrine
MTCR
|
-77.77 | - | - | $ 24.2 M | ||
|
Zealand Pharma A/S
ZEAL
|
-49.24 | - | 0.52 % | $ 821 M | ||
|
Myovant Sciences Ltd.
MYOV
|
-39.61 | - | -0.04 % | $ 2.62 B | ||
|
Bellerophon Therapeutics
BLPH
|
-249.92 | - | -74.18 % | $ 955 K | ||
|
Idera Pharmaceuticals
IDRA
|
-23.1 | - | -23.04 % | $ 26.6 M | ||
|
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | ||
|
Verona Pharma plc
VRNA
|
-36.57 | - | - | $ 69.7 B | ||
|
Atreca
BCEL
|
-62.67 | - | -11.76 % | $ 5.79 M | ||
|
Guardion Health Sciences
GHSI
|
1.33 | - | -0.31 % | $ 3.64 M | ||
|
Opiant Pharmaceuticals
OPNT
|
4.27 | - | - | $ 109 M | ||
|
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | ||
|
ImmunoGen
IMGN
|
-63.89 | - | - | $ 7.92 B | ||
|
Vascular Biogenics Ltd.
VBLT
|
-57.64 | - | -8.77 % | $ 12.4 M | ||
|
Cidara Therapeutics
CDTX
|
-79.06 | - | - | $ 1.41 B | ||
|
Iterum Therapeutics
ITRM
|
-55.55 | - | - | $ 591 K | ||
|
Virpax Pharmaceuticals
VRPX
|
-775.72 | - | -45.12 % | $ 2.85 M | ||
|
Navidea Biopharmaceuticals
NAVB
|
-347.18 | - | -2.99 % | $ 2.47 M | ||
|
Stealth BioTherapeutics Corp
MITO
|
-104.58 | - | - | $ 23.9 M | ||
|
OncoSec Medical Incorporated
ONCS
|
-156.23 | - | 31.87 % | $ 1.61 M | ||
|
BioDelivery Sciences International
BDSI
|
26.14 | - | -4.8 % | $ 255 M | ||
|
Albireo Pharma
ALBO
|
-11.27 | - | -0.23 % | $ 916 M | ||
|
bluebird bio
BLUE
|
-52.3 | - | - | $ 546 M | ||
|
Landos Biopharma
LABP
|
-57.66 | - | 0.58 % | $ 144 M | ||
|
CASI Pharmaceuticals
CASI
|
-42.62 | - | - | $ 35.4 M | ||
|
ContraFect Corporation
CFRX
|
-315.07 | - | -5.16 % | $ 5.39 M | ||
|
Sigilon Therapeutics
SGTX
|
-49.91 | - | - | $ 728 M |